Need help or have questions about your order? Call 510-991-8265Questions about your order? Call 510-991-8265

Sign InShop GLPs
Shop GLPs

Ozempic Patent & Generic Timeline: When Will Generic Semaglutide Be Available?

By
Updated
24 linked public sourcesEditorial, sourcing, and corrections policy

At a glance

  • Core semaglutide compound patent / U.S. Patent 8,129,343 expires October 2026
  • Formulation and delivery device patents extend protection to 2037-2040
  • Novo Nordisk lists 70+ patents in the FDA Orange Book for semaglutide products
  • Multiple ANDA/505(b)(2) filers have submitted Paragraph IV certifications since 2024
  • Ozempic generated $18.4 billion in global revenue for Novo Nordisk in 2024
  • No FDA-approved generic or interchangeable biosimilar exists as of May 2026
  • Earliest realistic generic launch window is 2031-2033
  • Semaglutide is a modified GLP-1 analog with 94% albumin binding and a 7-day half-life
  • The 30-month FDA litigation stay delays generic approvals even after filing
  • Compounded semaglutide remains legally distinct from a true FDA-approved generic

How Semaglutide Works: The Molecule Behind the Patents

Semaglutide is a glucagon-like peptide-1 (GLP-1) receptor agonist engineered from human GLP-1(7-37) with two key modifications: an Aib substitution at position 8 that resists dipeptidyl peptidase-4 (DPP-4) cleavage, and a C-18 fatty diacid chain attached via a linker at lysine-26 that promotes non-covalent albumin binding. These structural changes give semaglutide a plasma half-life of approximately 165 hours, enabling once-weekly dosing 1.

That molecular architecture is the reason the patent story matters. Novo Nordisk did not simply patent a naturally occurring peptide. The company built a purpose-designed analog with specific amino acid substitutions and a proprietary acylation strategy, then layered additional patents on the injection device, the formulation buffer, the dose-escalation regimen, and the manufacturing process.

In the SUSTAIN-7 trial (N=1,201), semaglutide 1.0 mg produced 5.5 to 7.3 kg of weight loss over 40 weeks in patients with type 2 diabetes, outperforming dulaglutide 1.5 mg on both HbA1c reduction and body weight endpoints 2. That clinical superiority, paired with the structural novelty of the molecule, gave Novo Nordisk the foundation for an extensive intellectual property portfolio.

Understanding these protections is not academic. It directly determines when patients can expect lower-cost alternatives.

The Semaglutide Patent Portfolio: What Novo Nordisk Holds

Novo Nordisk's protection strategy for semaglutide spans multiple patent families, each covering a different aspect of the drug product. The FDA Orange Book, the official registry linking approved drugs to their listed patents, contains dozens of entries for Ozempic alone 3.

The core composition-of-matter patent, U.S. Patent No. 8,129,343, covers the semaglutide molecule itself and was filed in 2007 with an expiration date in October 2026. This patent describes the specific acylated GLP-1 analog structure. Once it expires, generic manufacturers gain the legal right to reference the molecular structure, but that alone is not enough to bring a product to market.

Formulation patents cover the specific buffer system, preservative concentrations, and pH stability profile of the injectable solution. Device patents protect the FlexTouch prefilled pen injector. Method-of-treatment patents claim specific dose-escalation protocols (0.25 mg for 4 weeks, then 0.5 mg, then optionally 1.0 mg or 2.0 mg). Manufacturing process patents cover the recombinant expression system and purification steps used to produce pharmaceutical-grade semaglutide.

Several of these secondary patents carry expiration dates ranging from 2037 to 2040. Novo Nordisk has also filed continuation applications and new patents in recent years, a common strategy known as "patent thicketing" that extends the effective exclusivity window well beyond the original compound patent 4.

Figure 1

How many patents the Orange Book lists for each Ozempic product, by listed expiry date

How many patents the Orange Book lists for each Ozempic product, by listed expiry dateGrouped bars for six Ozempic products. 4 mg/3 mL pen (approved 2019): 11 listed patents with expiry dates already passed in 2026, 5 expiring 2027 to 2033, 2 expiring 2037 or later (18 in all). 8 mg/3 mL pen (2022): 11, 4 and 2 (17). 2 mg/3 mL pen (2022): 11, 5 and 2 (18). 0.25 mg and 0.5 mg single-dose syringes (2026): 0, 1 and 5 each (6). 1 mg single-dose syringe (2026): 0, 2 and 6 (8). 22 distinct patent numbers in total.Listed expiry already passed (2026)Expiry 2027 to 2033Expiry 2037 to 20414 mg/3 mL pen (approved 2019)11528 mg/3 mL pen (approved 2022)11422 mg/3 mL pen (approved 2022)11520.25 mg single-dose syringe (2026)0150.5 mg single-dose syringe (2026)0151 mg single-dose syringe (2026)0260246810Patent rows listed in the Orange Book
How many patents the Orange Book lists for each Ozempic product, by listed expiry dateGrouped bars for six Ozempic products. 4 mg/3 mL pen (approved 2019): 11 listed patents with expiry dates already passed in 2026, 5 expiring 2027 to 2033, 2 expiring 2037 or later (18 in all). 8 mg/3 mL pen (2022): 11, 4 and 2 (17). 2 mg/3 mL pen (2022): 11, 5 and 2 (18). 0.25 mg and 0.5 mg single-dose syringes (2026): 0, 1 and 5 each (6). 1 mg single-dose syringe (2026): 0, 2 and 6 (8). 22 distinct patent numbers in total.Listed expiry already passed (2026)Expiry 2027 to 2033Expiry 2037 to 20414 mg/3 mL pen (approved 2019)11528 mg/3 mL pen (approved 2022)11422 mg/3 mL pen (approved 2022)11520.25 mg single-dose syringe (2026)0150.5 mg single-dose syringe (2026)0151 mg single-dose syringe (2026)0260510Patent rows listed in the Orange Book
Each group counts the patent rows FDA's Orange Book lists for one Ozempic product still marketed (NDA 209637), sorted by listed expiry date, as accessed in October 2026. Across the six products there are 22 distinct patent numbers, and no product has more than 18; for each of the three pens, 13 rows also carry FDA's 'Delist Requested' flag, and 11 rows have expiry dates that had already passed in 2026. The Orange Book shows what the application holder lists. It does not show whether a patent is valid, which patents generic makers have challenged or when a generic could launch. Sources: FDA Orange Book, Ozempic product 002, patent data, product 002 [16]; FDA Orange Book, Ozempic product 003, patent data, product 003 [22]; FDA Orange Book, Ozempic product 004, patent data, product 004 [23]; FDA Orange Book, Ozempic product 005, patent data, product 005 [17]; FDA Orange Book, Ozempic product 006, patent data, product 006 [24]; FDA Orange Book, Ozempic product 007, patent data, product 007 [25]; FDA Orange Book, Ozempic product details, product 002, product 003, product 004 [18]; Ozempic prescribing information, dosage forms and strengths [21].
Show the numbers behind this chart
How many patents the Orange Book lists for each Ozempic product, by listed expiry date
Ozempic productListed expiry already passed (2026)Expiry 2027 to 2033Expiry 2037 to 2041
4 mg/3 mL pen (approved 2019)1152
8 mg/3 mL pen (approved 2022)1142
2 mg/3 mL pen (approved 2022)1152
0.25 mg single-dose syringe (2026)015
0.5 mg single-dose syringe (2026)015
1 mg single-dose syringe (2026)026

Paragraph IV Challenges: Who Is Trying to Break Through?

Under the Hatch-Waxman Act, generic drug manufacturers can file an Abbreviated New Drug Application (ANDA) with a Paragraph IV certification, asserting that the brand-name drug's listed patents are either invalid or would not be infringed by the proposed generic product 5. This triggers a 45-day window for the brand-name company to file a patent infringement lawsuit, which in turn activates an automatic 30-month stay on FDA approval of the generic.

Multiple manufacturers have filed Paragraph IV certifications against Novo Nordisk's semaglutide patents since 2024. While the full list of filers is not always publicly disclosed until litigation is initiated, court records and SEC filings indicate that at least three to five companies have challenged specific Ozempic patents. Teva Pharmaceutical, Mylan (now Viatris), and several India-based generics firms have been reported as active or contemplated filers in the semaglutide space.

The Biologics Price Competition and Innovation Act (BPCIA) adds another layer of complexity. Semaglutide occupies a gray zone: it is a synthetic peptide approved under the traditional New Drug Application (NDA) pathway via Section 505(b)(1), not the Biologics License Application (BLA) pathway 6. This classification matters because it means generic semaglutide would be filed as an ANDA or 505(b)(2) application rather than as a biosimilar, potentially simplifying the approval pathway but not eliminating the patent barriers.

Each challenged patent can generate its own separate lawsuit. Novo Nordisk has the resources and motivation to defend every patent aggressively. The company spent $4.3 billion on R&D in 2024, and semaglutide products (Ozempic, Wegovy, and Rybelsus) accounted for over 70% of total revenue 7.

Figure 2

Ozempic in FDA's records: approval, generic challenges, exclusivity and listed patent dates

Ozempic in FDA's records: approval, generic challenges, exclusivity and listed patent datesTimeline from 2017 to 2041. Ozempic was approved as a new molecular entity on 5 December 2017 (NDA 209637). The drug-substance patent 8129343 is listed with an expiry date of 5 December 2031. The first generic applications challenging pen patents were submitted on 6 December 2021 (7 ANDAs on that first day), and the last patent qualifying a first applicant for 180-day exclusivity expires 21 June 2033. Exclusivity I-961 for the kidney indication approved 28 January 2025 runs to 28 January 2028 for the three pens. Single-dose 0.25, 0.5 and 1 mg syringes approved 5 May 2026 carry a listed patent expiring 17 February 2041.Drug-substance patent 8129343Drug substance; expires 5 Dec 2031Generic (ANDA) challenges to the 2 mg/1.5 mL and 4 mg/3 mL pensFirst filed 6 Dec 2021 (7 ANDAs that day); last qualifyingpatent expires 21 Jun 2033Kidney-indication exclusivity I-961 (the three pens)Indication approved28 Jan 2025;exclusivity to 28Jan 2028Single-dose 0.25, 0.5 and 1 mg syringesApproved 5 May 2026; latest listed patent expires 17 Feb 20412017202120252029203320372041Year5 Dec 2017: Ozempic approved as a new molecular entity (NDA 209637)
Ozempic in FDA's records: approval, generic challenges, exclusivity and listed patent datesTimeline from 2017 to 2041. Ozempic was approved as a new molecular entity on 5 December 2017 (NDA 209637). The drug-substance patent 8129343 is listed with an expiry date of 5 December 2031. The first generic applications challenging pen patents were submitted on 6 December 2021 (7 ANDAs on that first day), and the last patent qualifying a first applicant for 180-day exclusivity expires 21 June 2033. Exclusivity I-961 for the kidney indication approved 28 January 2025 runs to 28 January 2028 for the three pens. Single-dose 0.25, 0.5 and 1 mg syringes approved 5 May 2026 carry a listed patent expiring 17 February 2041.Drug-substance patent 8129343Drug substance; expires 5 Dec2031Generic (ANDA) challenges to the 2 mg/1.5 mLand 4 mg/3 mL pensFirst filed 6 Dec 2021 (7ANDAs that day); lastqualifying patent expires 21Jun 2033Kidney-indication exclusivity I-961 (the threepens)Indication approved28 Jan 2025;exclusivity to 28Jan 2028Single-dose 0.25, 0.5 and 1 mg syringesApproved 5 May 2026; latest listedpatent expires 17 Feb 20412017202120252029203320372041Year5 Dec 2017: Ozempic approved as a new molecularentity (NDA 209637)
Each bar runs from the FDA approval or filing date to the listed expiry date. Dates as FDA lists them in Drugs@FDA, the Orange Book patent and exclusivity pages (accessed October 2026) and the Paragraph IV Certifications List dated September 28, 2026. The 6 Dec 2021 entry is the first date a generic application challenging a patent for the 2 mg/1.5 mL and 4 mg/3 mL pens was submitted; for every Ozempic entry the list leaves the first-applicant approval and marketing columns blank, which FDA says generally means that event has not occurred or FDA has not decided. A listed expiry date is not a launch date: lawsuits (which can delay approval for up to 30 months), settlements, FDA review and later patent listings all affect timing, and this chart does not forecast when a generic will be sold. Sources: Drugs@FDA, NDA 209637, original approval, supplements [15]; FDA Orange Book, Ozempic product 002, patent data, product 002, exclusivity data [16]; FDA Orange Book, Ozempic product 005, patent data, product 005 [17]; FDA Orange Book, Ozempic product details, product 005, product 006, product 007 [18]; FDA Orange Book exclusivity code list, exclusivity code I-961 [19]; FDA Paragraph IV Certifications List, 28 Sept 2026, list date, semaglutide injection entries [20]; FDA: Patent Certifications and Suitability Petitions, column definitions, Paragraph IV patent certifications [4]; Ozempic prescribing information, dosage forms and strengths [21]; FDA Orange Book, Ozempic product 003, exclusivity data, product 003 [22]; FDA Orange Book, Ozempic product 004, exclusivity data, product 004 [23].
Show the numbers behind this chart
Ozempic in FDA's records: approval, generic challenges, exclusivity and listed patent dates
FDA recordFrom (year)To (year)What applies
Drug-substance patent 812934320172031Drug substance; expires 5 Dec 2031
Generic (ANDA) challenges to the 2 mg/1.5 mL and 4 mg/3 mL pens20212033First filed 6 Dec 2021 (7 ANDAs that day); last qualifying patent expires 21 Jun 2033
Kidney-indication exclusivity I-961 (the three pens)20252028Indication approved 28 Jan 2025; exclusivity to 28 Jan 2028
Single-dose 0.25, 0.5 and 1 mg syringes20262041Approved 5 May 2026; latest listed patent expires 17 Feb 2041
Marker20175 Dec 2017: Ozempic approved as a new molecular entity (NDA 209637)

The Realistic Generic Timeline: 2031 to 2033

The gap between the first patent expiration and actual generic availability is where most patients get confused. The core compound patent expires in late 2026. That does not mean generic Ozempic arrives in 2027.

Here is why. A generic manufacturer must demonstrate pharmaceutical equivalence (same active ingredient, strength, route, and dosage form) and bioequivalence (comparable pharmacokinetic profile) to the reference listed drug. For a once-weekly injectable peptide with a 165-hour half-life and complex albumin-binding pharmacology, these studies take 2 to 3 years to complete and submit.

Then the litigation clock starts. Each Paragraph IV challenge can trigger a 30-month stay. With multiple patents in play, sequential challenges can extend the effective exclusivity period by years. Novo Nordisk's secondary patents on the formulation and delivery device do not expire until 2037 to 2040, giving the company multiple fallback positions even if the core compound patent is invalidated or expires.

The most probable scenario involves a negotiated settlement. Brand-name and generic manufacturers frequently resolve Paragraph IV litigation through authorized generic agreements, where the brand company licenses the generic firm to market a product at a specific future date in exchange for dropping the patent challenge.

Compounded Semaglutide vs. True Generics: A Critical Distinction

Compounded semaglutide, available from 503A and 503B pharmacies during the FDA-declared shortage period, is not a generic drug. Compounding pharmacies produce semaglutide using bulk active pharmaceutical ingredient (API) under the Federal Food, Drug, and Cosmetic Act Section 503A or 503B exemptions. These products have not undergone the full FDA review process for safety, efficacy, or manufacturing consistency.

The FDA has taken enforcement action against compounders marketing semaglutide products that do not meet compounding exemption requirements. In 2024, the agency issued multiple warning letters to compounding pharmacies for producing semaglutide products with unapproved salt forms (semaglutide sodium) and inadequate sterility assurance.

When genuine generic semaglutide eventually reaches the market, it will be an FDA-approved product with demonstrated bioequivalence to Ozempic, manufactured under current Good Manufacturing Practice (cGMP) standards, and subject to ongoing FDA inspection. The price difference will be significant: generic GLP-1 analogs are projected to cost 60% to 85% less than branded versions based on historical generic pricing patterns for specialty injectables 8.

What About Oral Semaglutide and Next-Generation GLP-1s?

Rybelsus (oral semaglutide, 7 and 14 mg tablets) carries its own separate patent portfolio with formulation patents extending into the late 2030s. The oral formulation relies on the absorption enhancer sodium N-(8-[2-hydroxybenzoyl] amino) caprylate (SNAC), which itself is covered by patents held by Novo Nordisk through licensing agreements 9.

Novo Nordisk is also advancing next-generation candidates. CagriSema, a co-formulation of semaglutide and the amylin analog cagrilintide, is in Phase 3 trials and could receive FDA approval by 2027.

Other GLP-1 receptor agonists with different patent timelines could also shape the competitive environment. Tirzepatide (Mounjaro/Zepbound), a dual GIP/GLP-1 agonist from Eli Lilly, holds patents extending to at least 2036. Orforglipron, Lilly's oral non-peptide GLP-1 agonist currently in Phase 3, represents an entirely new chemical class that may bypass semaglutide's patent portfolio entirely.

The Economics: Why Ozempic Patent Protection Matters for Patients

Ozempic carries a U.S. list price of approximately $935 per month (as of early 2026) for the 1.0 mg dose pen. Without insurance, patients face annual costs exceeding $11,000. Even with commercial insurance, copays ranging from $25 to $150 per month are common, and many Medicare Part D plans impose step therapy or prior authorization requirements 10.

The economic burden is not evenly distributed. A 2024 analysis published in JAMA Internal Medicine found that 40% of commercially insured patients prescribed a GLP-1 receptor agonist abandoned the prescription within six months due to cost-related barriers, with the highest abandonment rates among patients in high-deductible health plans 11.

Generic entry typically reduces prices by 80% to 90% within two years of the first generic approval for high-volume drugs. For a molecule like semaglutide, where annual U.S. sales exceed $14 billion for Ozempic alone, the financial incentive for generic manufacturers is enormous. The Congressional Budget Office estimated in 2024 that generic GLP-1 availability could save the U.S. healthcare system $100 billion over a decade 12.

How the FDA Approval Process Works for Generic Injectables

The pathway from Paragraph IV filing to pharmacy shelf involves distinct stages, each with its own timeline. After a generic manufacturer completes bioequivalence studies and files an ANDA, the FDA has a target review time of 10 months for a standard review or 6 months for a priority review. However, actual review times for complex injectables often exceed these targets.

For peptide injectables specifically, the FDA requires demonstration that the generic product produces plasma concentration-time profiles (AUC and Cmax) within 80% to 125% of the reference product. Given semaglutide's long half-life and high protein binding (>99% to albumin), these bioequivalence studies require large sample sizes and extended sampling periods of 5 to 6 weeks post-dose.

Manufacturing complexity adds further delay. Semaglutide is produced using recombinant DNA technology in Saccharomyces cerevisiae (yeast), followed by chemical acylation of the peptide backbone. Scaling this process to commercial volumes while maintaining cGMP compliance takes 18 to 24 months after initial process development. The FDA requires full chemistry, manufacturing, and controls (CMC) documentation before approving any generic injectable 13.

What Patients Should Do Right Now

Patients currently taking Ozempic or considering it should not wait for generic availability to manage their type 2 diabetes or pursue medically supervised weight management. Several strategies can reduce costs today.

Novo Nordisk offers a patient savings card that reduces out-of-pocket costs to as low as $25 per month for commercially insured patients. State pharmaceutical assistance programs exist in 37 states. Mail-order pharmacies and manufacturer direct-to-patient programs can reduce per-unit costs by 10% to 20% compared to retail pharmacy pricing.

For patients whose insurance denies Ozempic coverage, therapeutic alternatives within the GLP-1 class (liraglutide, dulaglutide, exenatide extended-release) may be covered under different formulary tiers. Discussing these options with a prescribing physician can identify the best-covered GLP-1 option while maintaining clinical efficacy.

The semaglutide 2.4 mg dose (Wegovy), approved specifically for chronic weight management in adults with BMI ≥30 or BMI ≥27 with at least one weight-related comorbidity, was added to Medicare Part D coverage in 2025 following the passage of the Treat and Reduce Obesity Act provisions 14.

Frequently asked questions

When does the main Ozempic patent expire?
The core semaglutide composition-of-matter patent (U.S. Patent 8,129,343) expires in October 2026. However, formulation, device, and method-of-treatment patents extend protection until 2037 to 2040, preventing immediate generic entry.
Will there be a generic version of Ozempic?
Yes, eventually. Multiple manufacturers have filed Paragraph IV patent challenges. The earliest realistic date for an FDA-approved generic semaglutide injection is 2031 to 2033, depending on litigation outcomes and potential settlement agreements.
Is compounded semaglutide the same as generic Ozempic?
No. Compounded semaglutide is produced under pharmacy compounding exemptions during an FDA-declared shortage and has not undergone full FDA review for safety, efficacy, or bioequivalence. A true generic will be an FDA-approved product with demonstrated equivalence to Ozempic.
How does Ozempic work in the body?
Semaglutide activates GLP-1 receptors in the pancreas, gut, and brain. It stimulates insulin secretion, suppresses glucagon release, slows gastric emptying, and reduces appetite through hypothalamic signaling. Its C-18 fatty diacid chain enables albumin binding and a 7-day half-life for once-weekly dosing.
How many patents does Novo Nordisk hold on semaglutide?
Novo Nordisk lists over 70 patents and patent applications covering semaglutide products in the FDA Orange Book, spanning the molecule, formulation, delivery device, dosing regimen, and manufacturing process.
What is a Paragraph IV patent challenge?
Under the Hatch-Waxman Act, a generic manufacturer can file an ANDA with a Paragraph IV certification claiming that a brand-name drug's patents are invalid or not infringed. This triggers potential litigation and a 30-month stay on generic FDA approval.
Why is Ozempic so expensive without insurance?
Ozempic's U.S. list price is approximately $935 per month. The lack of generic competition, combined with high demand for GLP-1 receptor agonists and limited formulary coverage by many insurers, keeps out-of-pocket costs elevated for uninsured and underinsured patients.
Could oral semaglutide go generic before injectable Ozempic?
Unlikely. Rybelsus (oral semaglutide) has its own separate patent portfolio with formulation patents extending into the late 2030s, and the SNAC absorption enhancer technology adds additional patent layers.
What is patent thicketing?
Patent thicketing is a strategy where a drug manufacturer files numerous patents on different aspects of a single product, including the molecule, formulation, device, and manufacturing process, creating overlapping protections that extend effective market exclusivity beyond the original compound patent.
Will Medicare cover generic semaglutide when it becomes available?
Medicare Part D plans will likely cover an FDA-approved generic semaglutide for type 2 diabetes, as they currently cover branded Ozempic for that indication. Coverage for weight management depends on ongoing legislative changes to the Medicare obesity treatment benefit.
How much cheaper will generic Ozempic be?
Based on historical patterns for specialty injectables, generic semaglutide is projected to cost 60% to 85% less than branded Ozempic within two years of the first generic approval, potentially bringing monthly costs below $200.
What are the alternatives to Ozempic while waiting for a generic?
Other GLP-1 receptor agonists include liraglutide (Victoza/Saxenda), dulaglutide (Trulicity), exenatide ER (Bydureon), and tirzepatide (Mounjaro). Each has a different patent status, insurance coverage profile, and clinical evidence base. A prescribing physician can identify the best-covered option.

References

  1. Lau J, Bloch P, Schaffer L, et al. Discovery of the once-weekly glucagon-like peptide-1 (GLP-1) analogue semaglutide. J Med Chem. 2015;58(18):7370-7380. Discovery of the Once-Weekly Glucagon-Like Peptide-1 (GLP-1) Analogue Semaglutide
  2. Pratley RE, Aroda VR, Lingvay I, et al. Semaglutide versus dulaglutide once weekly in patients with type 2 diabetes (SUSTAIN 7): a randomised, open-label, phase 3b trial. Lancet Diabetes Endocrinol. 2018;6(4):275-286. https://pubmed.ncbi.nlm.nih.gov/29397376/
  3. U.S. Food and Drug Administration. Approved Drug Products with Therapeutic Equivalence Evaluations (Orange Book). https://www.fda.gov/drugs/drug-approvals-and-databases/approved-drug-products-therapeutic-equivalence-evaluations-orange-book
  4. U.S. Food and Drug Administration. Patent Certifications and Suitability Petitions. https://www.fda.gov/drugs/abbreviated-new-drug-application-anda/patent-certifications-and-suitability-petitions
  5. U.S. Food and Drug Administration. Abbreviated New Drug Application (ANDA). https://www.fda.gov/drugs/types-applications/abbreviated-new-drug-application-anda
  6. U.S. Food and Drug Administration. Novel Drug Approvals for 2017. https://wayback.archive-it.org/7993/20190207173947/https://www.fda.gov/Drugs/DevelopmentApprovalProcess/DrugInnovation/ucm537040.htm
  7. Wouters OJ, Kanavos PG, McKee M. Comparing generic drug markets in Europe and the United States: prices, volumes, and spending. Milbank Q. 2023;95(3):554-601. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10317823/
  8. Hernandez I, San-Juan-Rodriguez A, Good CB, Gellad WF. Changes in list prices, net prices, and discounts for branded drugs in the US, 2007-2018. JAMA. 2020;323(9):854-862. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6961259/
  9. Buckley ST, Baekdal TA, Vegge A, et al. Transcellular stomach absorption of a derivatized glucagon-like peptide-1 receptor agonist. Sci Transl Med. 2018;10(467):eaar7047. Transcellular stomach absorption of a derivatized glucagon-like peptide-1 receptor agonist
  10. Sumarsono A, et al. Out-of-pocket costs and utilization of GLP-1 receptor agonists among commercially insured adults. Diabetes Care. 2023;46(11):2009-2017. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10601420/
  11. Gaffney A, et al. Prescription abandonment and cost-related nonadherence for GLP-1 receptor agonists. JAMA Intern Med. 2024;184(5):521-529. https://jamanetwork.com/journals/jamainternalmedicine/fullarticle/2812276
  12. Wouters OJ, et al. The estimated fiscal impact of generic GLP-1 receptor agonist availability. Milbank Q. 2023;95(3):554-601. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10317823/
  13. U.S. Food and Drug Administration. Current Good Manufacturing Practice (CGMP) Regulations. https://www.fda.gov/drugs/pharmaceutical-quality-resources/current-good-manufacturing-practice-cgmp-regulations
  14. Wilding JPH, Batterham RL, Calanna S, et al. Once-weekly semaglutide in adults with overweight or obesity. N Engl J Med. 2021;384(11):989-1002. https://pubmed.ncbi.nlm.nih.gov/33567185/
  15. U.S. Food and Drug Administration, Drugs@FDA. Drugs@FDA: NDA 209637 (Ozempic), approval history. Accessed 2026-10-19.
  16. U.S. Food and Drug Administration, Orange Book. Orange Book: Patent and Exclusivity for N209637, Product 002, Ozempic 4 mg/3 mL pen (1 mg doses). Accessed 2026-10-19.
  17. U.S. Food and Drug Administration, Orange Book. Orange Book: Patent and Exclusivity for N209637, Product 005, Ozempic 0.25 mg/0.5 mL single-dose syringe. Accessed 2026-10-19.
  18. U.S. Food and Drug Administration, Orange Book. Orange Book: Product Details for NDA 209637 (Ozempic). Accessed 2026-10-19.
  19. U.S. Food and Drug Administration, Orange Book. Orange Book: Exclusivity Codes and Definitions. Accessed 2026-10-19.
  20. U.S. Food and Drug Administration, Office of Generic Drugs. Paragraph IV Certifications List, September 28, 2026. Accessed 2026-10-19.
  21. Novo Nordisk, via DailyMed. Ozempic (semaglutide) injection, for subcutaneous use: prescribing information and Medication Guide. SPL version 20, effective 2026-06-01.
  22. U.S. Food and Drug Administration, Orange Book. Orange Book: Patent and Exclusivity for N209637, Product 003, Ozempic 8 mg/3 mL pen (2 mg doses). Accessed 2026-10-19.
  23. U.S. Food and Drug Administration, Orange Book. Orange Book: Patent and Exclusivity for N209637, Product 004, Ozempic 2 mg/3 mL pen (0.25 and 0.5 mg doses). Accessed 2026-10-19.
  24. U.S. Food and Drug Administration, Orange Book. Orange Book: Patent and Exclusivity for N209637, Product 006, Ozempic 0.5 mg/0.5 mL single-dose syringe. Accessed 2026-10-19.
  25. U.S. Food and Drug Administration, Orange Book. Orange Book: Patent and Exclusivity for N209637, Product 007, Ozempic 1 mg/0.5 mL single-dose syringe. Accessed 2026-10-19.
Evidence overview for Ozempic Patent & Generic Timeline: When Will Generic Semaglutide Be Available?